XL-647 Size:Solid 10 mg CCOCC(O)COC1C=CC(=CC=1)NC(=O)CC[S+](C)C

CCOCC(O)COC1C=CC(=CC=1)NC(=O)CC[S+](C)C

InChi: InChI=1S/C25H25F3N2O2/c1-14-10-17-16-6-4-5-7-20(16)29-23(17)24(30(14)13-25(2

8-tetraenoic acid

3-tricarboxylate

ML-277 shows 1000-fold greater selectivity for the Chk2 serine/threonine kinase than for the Cdk1/B and CK1 kinases (for which IC50 = 12 μM and 17 μM

XL-647 Size:Solid 10 mg CCOCC(O)COC1C=CC(=CC=1)NC(=O)CC[S+](C)CTesevatinib, also known as XL647, EXEL 7647 and KD 019, is a n orally bioavailable small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. XL647 binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth